Last reviewed · How we verify

NCT06640010

Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

Recruiting now Last updated 6 January 2026
What this trial tests

trial testing Non-Interventional Study in Hematopoietic and Lymphatic System Neoplasm in 30 participants. Currently enrolling.

Timeline
13 January 2025
Primary endpoint
15 December 2026
15 December 2026

Quick facts

Lead sponsorMayo Clinic
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment30
Start date13 January 2025
Primary completion15 December 2026
Estimated completion15 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Hematopoietic and Lymphatic System Neoplasm or Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Hematopoietic and Lymphatic System Neoplasm

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06640010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing